Fresenius Invests in BioIntellisense AI Platform
“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.
Read the full article » | Posted 09-12-2019
Related Articles
- Fresenius Medical Care named Shervin Korangy as CEO Posted 10-22-2026
- Aligning Clinical Excellence with Health System Goals Through PD in Value-Based Models Posted 10-22-2026
- Update on National Institutes of Health websites Posted 10-22-2026
- What to Know About the American Society of Nephrology Kidney Week Posted 10-22-2026